In this issue of Acta Radiologica, NIELSEN et al. (1) present their experience with radiofrequency ablation (RFA) in selected patients with colorectal liver metastases (CRLM) downsized by chemotherapy.
Around 30% of patients with colorectal cancer (CRC) will develop hepatic metastases at some point during the course of the disease. The establishment of resection as the gold standard for patients with resectable CRLM has been driven by enthusiastic surgeons, but we have to keep in mind that the scientific support for resection is only based on level-II scientific evidence because of lack of randomized, controlled trials (RCT). After microscopic radical resection (R0), the expected 5-year survival is around 35% and even higher in recent selected series.
Presently, around 10% of patients with CRLM are candidates for local treatment. This number will certainly grow with the introduction of newer surgical (e.g., preoperative portal vein embolization and two-stage resection) and ablative techniques, and markedly enhanced efficacy of systemic and regional chemotherapy. The optimal combination of these different modalities must be agreed upon by a multidisciplinary team (MDT) including, at a minimum, liver surgeons, oncologists, and interventional radiologists.
Over the past decade, the efficacy of chemotherapy has been markedly improved. Modern combination chemotherapy with irinotecan or oxaliplatin generates tumor regression in 50% of patients with metastatic CRC. Progression-free survival is prolonged to 10 months, and median overall survival (OS) approaches 24 months, but only in fit, selected patients who are potential candidates for inclusion in clinical trials. The addition of novel biologic agents (e.g., cetuximab or bevacizumab), especially in patients with liver-only disease, further increase response rates to 70% and, subsequently, the proportion of patients who are candidates for supplementary local therapy. It is very important that the oncologist regularly consider the possibility for either resection or local ablative techniques (LAT), because even with response rates around 70%, the number of cases of complete pathological response is still less than 5%.
Survival of patients with metastatic CRC is correlated to tumor burden (e.g., number of metastatic sites) and to tumor response. Thus, median OS is usually longer in patients with liver-only disease, particularly in a selected subgroup of patients who experience tumor regression, in whom median OS may be 3 years or more. For these reasons, systemic therapy has been incorporated in modern treatment strategies for patients with CRLM but has also increased treatment complexity. Perioperative systemic therapy is used to reduce the risk of recurrence in patients with resectable CRLM, but major tumor regression has also permitted salvage surgery in 10Á 30% of patients with initially unresectable CRLM. It is again important to note that chemotherapy alone is not administered with curative intent, but as a downsizing or neoadjuvant therapy in patients with liver-only CRC.
In 2001, RFA was approved by the FDA in patients with unresectable CRLM. Since then, an increasing number of patients have received RFA as an adjunct to resection and as an alternative to resection in unfit patients. Unfortunately, an increasing number of patients with resectable CRLM have been treated with LAT, even in the absence of a proper evaluation by an MDT.
In their paper, NIELSEN et al. (1) calculate outcome from the diagnosis of liver metastases and conclude that a median survival of 39 months suggests an additional effect of RFA compared to systemic chemotherapy alone. Hopefully, their conclusion will be confirmed in larger, well-conducted trials. The median survival of a selected subgroup of patients with liver-only CRC and who obtain major tumor regression after systemic treatment is not known for certain, but it may be 39 months even without supplementary local therapy. It is also important to note that the chemotherapeutics are not reported in their study, but the regimens may not live up to present gold standards.
The question is not whether chemotherapy or RFA is the treatment of choice, and outcome from these different treatment modalities should not and cannot reasonably be compared. These different modalities are not in competition. Instead, we must plan well-conducted clinical trials that can answer at least some of the many unanswered questions.
LAT has been directly compared to surgical resection, but only in patients with hepatocellular carcinoma B5 cm, not in CRLM. Numerous retrospective or prospective series have tried to compare percutaneous LAT, laparoscopic LAT, or open LAT to each other or to resection, but all these studies in CRLM are hampered due to large selection bias that makes any meaningful comparison worthless. The only possible method to confirm the efficacy of LAT is to plan and conduct proper RCTs, but has the time come to conduct such studies?
Based on an excellent review, MULIER et al. proposed an RCT with comparison of RFA to surgical resection in resectable CRLM B3 cm (2). However, others argue that it is not yet time for RCT in patients with resectable CRLM (3).
Several chemotherapy regimens are known to induce hepatic injury, such as hepatic steatosis and sinusoidal obstruction syndrome (4) . In such cases, surgical morbidity is increased, but mortality is not higher if duration of preoperative chemotherapy is limited to 3 months. No reports of the outcome of RFA in chemotherapy-induced hepatic injury have been published. Attention to this rather poorly described phenomenon in an aggressive approach in CRLM is a challenge for MDTs, and indeed research in this field is warranted.
We believe that the time has come to conduct and participate in RCTs comparing resection and LAT in a selected group of patients, because LAT, with or without data from RCT, is going to be used in everyday practice, including patients with resectable CRLM.
Like surgical resection, ablation of CRLM relies on level-II scientific evidence, and a well-planned and conducted RCT comparing the two methods of treatment is warranted. Until then, ablation in CRLM should be limited to patients unable to tolerate resection and to patients with truly nonresectable CRLM. Every patient with CRLM must be carefully evaluated by an MDT, and the optimal treatment chosen in respect to type, extent, and location of tumor, as well as comorbidity. At present, the decision very often involves a combination of surgical resection and ablation, if CRLM are downsized by chemotherapy.
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